Dr. David Nelson and Dr. Roniel Cabrera Try to Give Liver Cancer Patients More Time

Sorafenib Dr. David Nelson and Dr. Roniel Cabrera Try to Give Liver Cancer Patients More Time Photo

Nexavar / Sorafenib (canadiannetmall.com)

University of Florida physicians and researchers are looking to improve life expectancy for patients with liver cancer.

Research started in November with 120 patients with inoperable cancer, and is expected to continue for a year while being funded by the only existing medication that currently treats advanced stages of liver cancer, Sorafenib.

“Quality is just as important, if not more important, than quantity of life,” said Dr. Roniel Cabrera, leading researcher and a UF assistant professor of medicine. “The trial has the potential to break new ground in the treatment of primary liver cancer,” Dr. Cabrera said. (alligator.org)

Currently there are issues with the medication’s side effects, so the testing will follow results of lower dosage.

Dr. David Nelson, director of UF’s Clinical and Translational Science Institute, said:

“In this devastating disease, this approach is essential to yield the best treatment opportunities for patients with advanced disease,” said Dr. David Nelson.  Some patients can’t tolerate the pill for long periods of time because of the side effects. He hopes this research will change that. (alligator.org)